Click Here to return To Results

 

Alemtuzumab CARE-MS II 5-year follow-up Neurol 89:1117-1126, Coles, A.J.,et al, 2017 See this aricle in Pubmed Article Abstract Alemtuzumab provides durable efficacy through 5 years in patients with an inadequate response to prior therapy in the absence of continuous treatment.

Related Tags

(click to filter results - removes previous filter) alemtuzumab brain atrophy efficacy immunomodulation monoclonal antibodies MRI,abnormal multiple sclerosis multiple sclerosis,relapsing multiple sclerosis,treatment of safety treatment of neurologic disorder

Click Here to return To Results